|
Tomorrow's Treatments Today |
|
Saturday, 12 July 2008 |
|
Welcome to Beike Biotechnology's web site. The purpose of this web site is to give you information not only on Beike as a company but also to give information on treatments available to patients outside of China. Beike is a biotechnology company that is contracted to provide stem cells for treatment at twenty-four hospitals in China. Safety is our number one priority so we only partner with hospitals that are ranked in the top three in their city in terms of reputation and most of the hospitals have over 600 beds and every major department so that our patients can receive comprehensive treatment in a professional manner. Beike has selected the best hospitals for treatment for foreign patients judged by the hospital's environment, excellence of the doctors, nurses and rehabilitation staff and affordable cost. The treatments at these selected hospitals are comprehensive and we keep cost of treatment as low as possible so that we can help as many people as possible improve their quality of life. We practice compassionate therapy meaning our treatment protocols practiced by our partner hospitals include everything we have found beneficial based on our research to improve patients' quality of life. Our hospitals don't just inject you with stem cells, charge you a lot of money and send you home. Of the over 3,000 patients that have been treated with our stem cells, about 70 to 80% of patients are satisfied with their treatment depending on the ailment. This percentage is increasing as we become more intelligent in our patient selection. If our medical department does not believe you will benefit from the treatment, we will tell you and suggest you seek treatment elsewhere. We by no means guarantee improvement but our treatment protocol consists of multiple injections of stem cells accompanied by daily rehabilitation to ensure that if our stem cells can help your condition, you will get some improvement. We don't want anyone patient coming for treatment to expect miracles but a majority of our patients have reported improvement in quality of life. We have included some examples of improvements that patients have observed at the end of their treatment in our patient experiences section. It is important to note that these experiences are some of the better outcomes which are generally better than the average. Our treatment protocols are generally focused on injections of umbilical cord stem cells into the spinal cord fluid and intravenously. However, for certain cases of spinal cord injury, doctors will inject stem cells surgically. We often also provide bone marrow stem cells for patients with MS, Ataxia and spinal cord injuries. Our pipeline of future products include stem cells derived from amniotic membrane and iPS for which the Chinese government has supported us with significant funding for our partnership with China’s leading scientific university, Tsinghua Unversity. Based on the research and extensive clinical experience, our scientists believe (among other things) that the improvements our patients report partially result from the growth factors and other "nutrients" from our stem cells reinvigorating living but dysfunctional cells so patients with many neurological diseases do get measurable improvements. However, from practice, the best results reported are for spinal cord injury, cerebral palsy, optic nerve hypoplasia, multiple sclerosis, and ataxia. These conditions make up our main focus for current treatments and ongoing scientific study. We also have extensive experience and have done multiple studies using adult stem cells. Our scientists have nearly eighty publications published in Chinese journals and have done clinical studies starting as far back as 2001 when the first ALS patient in a safety trial. We are currently conducting international level clinical trials and expect to see results from our clinical studies published in leading international journals in late 2008 or early 2009. See our research section for more information on some of our publications. Please see more about us on About Us page. If you are in Europe, please go to the Beike Europe Website . If you are in Turkey, please go to the Beike Turkey website . If you are in India, please send your enquiry to Lalit Jaiswal and our India office at
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
|
|
Last Updated ( Friday, 18 July 2008 )
|
|
|
Beike Biotech Opens Comprehensive Global Stem Cell Storage and Processing Facility in China |
|
Thursday, 19 June 2008 |
 Taizhou, Jiangsu Province, CHINA, June 19, 2008–Shenzhen Beike Biotechnology Co., Ltd. (http://www.beikebiotech.com ), a worldwide leader in providing safe and effective stem cell applications for medical treatment, has commenced outfitting its 21,500 square foot comprehensive medical stem cell storage and processing facility in eastern China. When fully completed, the Jiangsu Stem Cell Storage Facility will be one of the most highly developed of its kind anywhere in the world, with advanced technology and safe conditions to properly freeze, store, and process a broad range of human stem cell samples for clinical application. The Stem Cell Storage Facility will initially provide stem cell banking for human umbilical cord blood stem cells, placenta stem cells, amniotic membrane stem cells, bone marrow stem cells, and later will also be able to house induced pluripotent stem cells (iPS). Considered the future for stem cell treatments, iPS cells are derived from cell reprogramming technologies and are a non-controversial potential alternative to embryonic stem cells. Like umbilical cord blood stem cells, iPS cells can be preserved for later use in fighting a range of disorders.
Initially, the facility will be used primarily for private banking of stem cells by individuals, but as the number of samples increases, it will focus on public banking for medical facilities with the aim of allowing Beike to become a global supplier for patients in need of stem cell transplants. Jiangsu Beike Biotechnology Co., Ltd., a subsidiary of Shenzhen Beike Biotechnology Co., Ltd., has been established to manage the facility.
Dr. Sean Hu, the Chairman of Beike Biotech said, “Stem cell storage is the next logical step for us given our years of experience in handling and culturing stem cells to successfully treat patients from all over the world. With this groundbreaking new storage facility, Beike now leapfrogs to the forefront of the global stem cell industry by providing a large and secure home for the ammunition doctors need to fight debilitating disorders worldwide.” |
|
Last Updated ( Friday, 20 June 2008 )
|
|
Read more...
|
|
|
Local Child Gets Sight Back After Stem Cell Treatment |
|
Wednesday, 14 May 2008 |
Source: NSB Observer
By Dan J. Beilstein
SOUTH DAYTONA — Six months ago, former Port Orange resident Abby Wolfe said she would do anything for her 18-month-old son, Elioe “Tre” Burgos III. Elioe’s vision was thought to be no better than 20/1200. He was blind, and diagnosed with Optic Nerve Hypoplasia (ONH). Doctors informed Ms. Wolfe and Elioe Burgos Sr. that young Elioe suffered from an underdevelopment of his optic nerve. According to doctors, ONH is not progressive or inherited. Ms. Wolfe’s decision to embark on a medical journey involved researching umbilical cord stem cell treatments to grow cells needed to help improve Elioe’s sight. But, that meant raising money to pay for the operations and travel to China — where stem cell research is legal. The frustrated parents soon learned there were no medical facilities in the United States that offered the treatment Elioe needed. Next stop, China. |
|
Last Updated ( Friday, 16 May 2008 )
|
|
Read more...
|
|
|
|